Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies

[PR Newswire] – INDIANAPOLIS, Oct. 2, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) announced today it will discontinue development of tabalumab­ — being studied for the treatment of systemic lupus erythematosus (SLE, . . . → Read More: Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference Market Update (NYSE:LLY): Lilly Declares Second-Quarter 2014 Dividend Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Reports First-Quarter 2014 Results